Get the Stockscreener App
6.10
3.71%
-0.235
Leonabio Inc stock is traded at $6.10, with a volume of 77,895.
It is down -3.71% in the last 24 hours and up +0.00% over the past month.
LeonaBio Inc is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
See More
Previous Close:
$6.335
Open:
$6.34
24h Volume:
77,895
Relative Volume:
28.18
Market Cap:
$24.06M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.07
$6.34
1-Week Range:
$6.07
$6.625
52-Week Range:
$6.07
$6.625
Leonabio Inc Stock (LONA) Company Profile
Name
Leonabio Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
6.10 | 24.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Leonabio Inc Stock (LONA) Latest News
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA" - Investing News Network
Athira Pharma (ATHA) Options to Be Delisted on January 12th - GuruFocus
Athira Pharma Rebrands as LeonaBio, Refocusing on Oncology - TipRanks
Athira Pharma announces name change to LeonaBio - TipRanks
Athira Pharma roars into the new year with rebrand to LeonaBio - Fierce Pharma
Athira Pharma changes name, ticker symbol - MSN
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy - Investing.com Nigeria
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy By Investing.com - Investing.com South Africa
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - Yahoo Finance
New breast cancer drug moves into late testing with $236M funding deal - Stock Titan
Athira Pharma Announces Reverse Stock Split - GlobeNewswire
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - marketscreener.com
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology - marketscreener.com
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND - marketscreener.com
Athira Pharma, Inc. Plans to Further Extend the Current OLEX for the Phase 2/3 LIFT-AD and Phase 2 ACT-AD Trials - marketscreener.com
Athira Pharma Provides 2023 Pipeline Outlook - marketscreener.com
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates - marketscreener.com
Alzheimer’s Disease Stock Cortexyme Craters on Trial Failure - Bloomberg
ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan
Leonabio Inc Stock (LONA) Financials Data
There is no financial data for Leonabio Inc (LONA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Leonabio Inc Stock (LONA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jan 02 '26 |
Sale |
6.88 |
1,644 |
11,311 |
10,189 |
| Litton Mark James | President and CEO |
Dec 31 '25 |
Option Exercise |
0.00 |
10,834 |
0 |
43,414 |
| Litton Mark James | President and CEO |
Jan 02 '26 |
Sale |
6.88 |
2,586 |
17,792 |
40,828 |
| Renninger Robert | Chief Financial Officer |
Dec 31 '25 |
Option Exercise |
0.00 |
1,236 |
0 |
13,154 |
| Renninger Robert | Chief Financial Officer |
Jan 02 '26 |
Sale |
6.88 |
297 |
2,043 |
12,857 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Dec 31 '25 |
Option Exercise |
0.00 |
3,667 |
0 |
21,557 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jan 02 '26 |
Sale |
6.88 |
876 |
6,027 |
20,681 |
| Worthington Mark | General Counsel and CCO |
Dec 31 '25 |
Option Exercise |
0.00 |
3,667 |
0 |
14,854 |
| Worthington Mark | General Counsel and CCO |
Jan 02 '26 |
Sale |
6.88 |
876 |
6,027 |
13,978 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
177,427 |
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):